Navigation Links
Akrimax Pharmaceuticals Announces Manufacturing Partnership
Date:1/6/2009

Signs Agreement with Global Healthcare Company

ROUSES POINT, N.Y., Jan. 6 /PRNewswire/ -- Akrimax Pharmaceuticals, LLC announced today a manufacturing agreement for the production of pharmaceutical products for a global company beginning in 2009. Akrimax was selected from several potential partners in a competitive process.

Akrimax President Alan L. Rubino said: "This agreement further validates Akrimax's decision to acquire the Rouses Point facility which possesses diverse manufacturing and packaging capabilities, and a spotless regulatory and safety record. We are pleased to announce this development as we are ahead of our planned schedule of bringing in new manufacturing partnerships to our Rouses Point facility."

Rubino also said: "Our contract manufacturing partnership enhances our strategic plan and showcases the quality of our people and our ability to execute at this facility. We are proving every day that Made in America pharmaceutical manufacturing is good business for our partners because of our high-quality manufacturing, competitive value and excellent track record with the FDA."

About Akrimax

Akrimax Pharmaceuticals, LLC is a privately-held, fully-integrated next-generation specialty pharmaceutical company concentrated on acquiring marketed products and developing select late-stage products to address disease states related to "metabolic syndrome." The company also owns a world-class plant in Rouses Point, NY with a highly skilled workforce. Akrimax manufactures its own products and develops select manufacturing partnerships. The plant encompasses 67.6 acres with 38 buildings, offering approximately 1 million sq. feet of manufacturing and packaging space. Akrimax was formed in 2007 and purchased the Rouses Point plant from Wyeth in January 2008.

Based in Cranford, NJ, Akrimax pursues unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products. Akrimax currently markets Inderal(R) LA and LoOvral(R) branded products and operates the manufacturing facility in conjunction with Wyeth during a transition period that runs through 2009. www.Akrimax.com

    For more information
    Timothy Soule: tsoule@akrimax.com
    Kevin Ellis: Kimbell Sherman Ellis: 800-498-5390 ext. 107:
    Kevin@kse50.com


'/>"/>
SOURCE Akrimax Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
3. AUDIO from Medialink and Solvay Pharmaceuticals: New Initiative Urges Women to Address Mens Health this New Year
4. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
5. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
6. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
7. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
9. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
10. Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis
11. SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Film Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ... position, rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... Monday, May 16, 2016, at its new location in the Exchange Furniture Mall at ... a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology: